Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases

doi:10.19803/j.1672-8629.2022.01.08

Abstract

Abstract: Objective To conduct a real-world study of Shengmai injection based on the hospital information system (HIS) in order to find out more about the clinical characteristics of elderly patients with cardiovascular diseases who use Shengmai injection (SMI). Methods The clinical data on 9 215 elderly patients with cardiovascular diseases treated in 29 tertiary hospitals between January 1, 2001 and December 31, 2016 was retrieved from the HIS database by R software to analyze the clinical characteristics of patients and ways in which Shengmai injection was used. Results There were 5 109 male patients and 4 035 female ones involved. The average age of these patients was (78.15±6.90) years, and their length of hospital stay averaged (25.39±19.88) days. Hypertension, respiratory tract infection and arrhythmia were the most common comorbidities. The main route of administration of SMI was intravenous drip (7 504 cases) and the average single dose was (55.79±18.06) ml. The average duration of treatment was (6.02±7.37) days. The most commonly used drug combinations included Tanreqing injection+ambroxol. Conclusion Analysis of the data on elderly patients with cardiovascular diseases has revealed some of the characteristics of these patients and ways of medication of SMI, which can help clinicians to use SMI rationally.

Key words: real world, Shengmai injection, cardiovascular diseases in the elderly, hospital information system, clinical characteristics

CLC Number:

R994.11

SUN Chunquan, XIE Yanming, HOU Hengyue. Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.

References

[1] WU JR, YANG SY, ZHANG XM, et al.Systematic review of Shengmai injection in the treatment of coronary heart disease and angina pectoris based on meta-analysis[J]. Journal of Chinese Experimental Prescriptions(中国实验方剂学杂志), 2015, 21(22): 222-225.
[2] WANG LM, GAO CJ, XIE LC, et al.Clinical study of Shengmai injection combined with lyophilized recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction with heart failure[J]. Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular and Cerebrovascular Diseases(中西医结合心脑血管病杂志), 2019,17(22): 3553-3556.
[3] ZHUANG Y, XIE BT, WENG SX, et al.Discussion on the design method of his“real world”integrated data warehouse for post marketing reevaluation of traditional Chinese medicine[J]. Journal of Traditional Chinese Medicine(中国中药杂志), 2011, 36(20): 2880.
[4] Drug intelligence data. Drug ATC code query system[EB/OL]. [2021-03-11] https://db.yaozh.com/atc/.2014-4-17/2019-9-15.
[5] National Pharmacopoeia Commission.Pharmacopoeia (Part I) of the People's Republic of China[中华人民共和国药典(一部)][M]. Beijing: China Pharmaceutical Science and Technology Press, 2020.
[6] The People's Government of the People's Republic of China. The Department of Human Resources and Social Security of the State Medicare Administration is concerned with the publication of the national basic medical insurance, workers'insurance and fertility insurance drug catalog (2020) notice[EB / OL]http://www.gov.cn/zhengce/zhengceku/2020-12/28/content_5574062.htm,202020-12-28/2021-03-11.
[7] CHEN Z, WU JJ.Research on medical data mining based on association rules[J]. Statistics and Decision(统计与决策), 2020, 36(6): 174-177.
[8] YANG ZJ, TANG M.Risk factors analysis of cardiovascular disease in elderly patients with coronary heart disease[J]. Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular and Cerebrovascular Diseases(中西医结合心脑血管病杂志), 2018,16(20): 3010-3013.
[9] HU MY, ZHAO Y, XU X, et al.Correlation between different blood glucose levels and cardiovascular risk factors in elderly patients with type 2 diabetes[J]. Journal of Chinese Diabetes(中国糖尿病杂志), 2015, 23(12): 1092-1095.
[10] LUO YZ, ZHAO YH, ZHANG HG.Analysis of the related factors of pulmonary infection in patients with coronary heart disease[J]. Journal of Chinese Hospital Infectiology(中华医院感染学杂志), 2014, 24(13): 3245-3247.
[11] LIU LN, ZHU XL, MA HF, et al.Meta analysis on risk factors of secondary pulmonary infection in Chinese elderly patients with heart failure[J]. Journal of Chinese Gerontology(中国老年学杂志), 2019, 39(23): 5652-5657.
[12] LIAO XJ, YIN T, LI CM, et al.Discussion on the relationship between over instructions of traditional Chinese medicine injection and adverse reactions[J]. Journal of Pharmacoepidemiol(药物流行病学杂志), 2018, 2(2): 104-108.
[13] LI WJ, LI XY, FAN XL.Overview of the consequences and causes of overdose of traditional Chinese medicine injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2011, 8(10): 611-613.
[14] KERNIS SJ, HARJAI KJ, STONE GW, et al.Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty[J]. J Am Coll Cardiol, 2004, 43(10): 1773-1779.
[15] XIAO Y, DONG PS, YANG XM.Expression of serum inflammatory factors in patients with acute coronary syndrome with pulmonary infection[J]. Journal of Chinese Hospital Infectiology(中华医院感染学杂志), 2015, 25(18): 4138-4140.
[16] Guidelines for rational use of drug in coronary heart disease (2nd edition)[J]. Journal of Chinese Medical Frontier (electronic edition)中国医学前沿杂志(电子版), 2018, 10(6): 1-130.
[17] FARIS RF, FLATHER M, PURCELL H, et al. Diuretics for heart failure[J]. Cochrane Database Syst Rev, 2012(2): CD003838.
[18] LIU Y, GAO ZY, FU CG, et al.Prevention and treatment of coronary heart disease by promoting blood circulation and removing blood stasis drugs: evidence based and prospect[J]. Journal of Chinese Evidence Based Medicine(中国循证医学杂志), 2018, 18(11): 1145-1150.
[19] FAN CP, DU HG, TIAN Y.Clinical application of Tanreqing injection in respiratory diseases[J]. Chinese Traditional Medicine Emergencies(中国中医急症), 2014, 23(10): 1878-1881.